Bristol-myers Squibb Stock News

Bristol Myers drug wins first U.S. approval for Graft versus Host Disease prevention Reuters

Biotech stocks reversed course and advanced solidly in the week ending Dec. 17, as an increase in risk aversion pushed investors to buy into defensive stocks. The sector also drew strength from some positive stock-specific news. Among the regulatory decisions for the week, the Food and Drug Administration gave the green light to argenx SE''s (NASDAQ: ARGX ) efgartigimod for the treatment of generalized myasthenia gravis. AstraZeneca plc (NASDAQ: AZN ) and Amgen, Inc. (NASDAQ: AMGN ) announced an FDA nod for their Tezspire as a treatment option for severe asthma for those aged 12 years and older. Bristol-Myers Squibb Company ''s (NYSE: BMY ) Orencia was approved for the prophylactic treatment of acute graft-versus-host disease. Calliditas Therapeutics AB (publ) (NASDAQ: CALT ) scored an FDA win for Tarpeyo, the first-approved treatment to reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk of rapid disease progression. Galera Therapeutics, Inc. (NASDAQ: Full story available on Benzinga.

Terril Brothers Inc. lowered its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 2.5% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 395,867 shares of the biopharmaceutical companys stock after selling 10,270 shares during the period. Bristol-Myers Squibb makes up approximately 5.8% of Terril Brothers Inc.s []

This Buffett holdings list from Kiplinger first appeared 9/16/21 online. YCharts and Dogs of The Dow also track this Buffett/Berkshire Batch. Here is your update from 12/15/21 YCharts data. 28 of 43 c

International Assets Investment Management LLC decreased its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 9.5% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 10,555 shares of the biopharmaceutical companys stock after selling 1,113 shares during the period. International Assets Investment Management LLCs holdings []

Brokerages forecast that Bristol-Myers Squibb (NYSE:BMY) will post $1.85 earnings per share for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for Bristol-Myers Squibbs earnings, with the highest EPS estimate coming in at $1.88 and the lowest estimate coming in at $1.81. Bristol-Myers Squibb reported earnings of $1.46 per share []

The Goldman Sachs Group initiated coverage on shares of Bristol-Myers Squibb (NYSE:BMY) in a report issued on Friday, Price Targets.com reports. The firm issued a buy rating and a $72.00 price objective on the biopharmaceutical companys stock. BMY has been the subject of a number of other research reports. Berenberg Bank cut their target price []

Related Stocks: BMY ,

Investors Alley Weakness Is Turning Into Opportunity For Bristol Myers Squibb (BMY) After falling from $68 to a about $55, the oversold pharmaceutical stock is just starting to pivot higher. From a current price of $60.82, wed like to see the stock retest $69.19. Over the last few days, Bristol Myers Squibb raised its quarterly dividend to $0.54 per share from $0.49, boosting the annual dividend to [] Weakness Is Turning Into Opportunity For Bristol Myers Squibb (BMY) Ian Cooper

Mcdonald Partners LLC raised its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 6.5% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 11,465 shares of the biopharmaceutical companys stock after buying an additional 699 shares during the period. Mcdonald Partners LLCs holdings in Bristol-Myers Squibb were []

According to new research study on Global Tyrosine Kinase Inhibitors Market 2027 covers worldwide, provincial, and nation level market size, pieces of the overall industry, market development rate investigation (incorporate Reason of most noteworthy and least pinnacle Market examination), ongoing

These three big-pharma stocks exploded higher this week.

Kinross Gold Corporation (NYSE:KGC) with the stream of 7.34% also noticed, India Bristol-Myers Squibb Company (NYSE:BMY) encountered a rapid change of 2.57% in the last hour of Thursdays trading session. The post Early Moves to Watch: Kinross Gold Corporation (NYSE:KGC), Bristol-Myers Squibb Company (NYSE:BMY) appeared first on Stocks Equity .

On Monday, Bristol-Myers Squibb Co. (NYSE:BMY) shares gained 2.5%, extending this week's gains to over 10%. The company recently announced a share buyback program worth $15 billion.

The health care sector is often a favorite of the dividend growth investor class for a number of reasons.